PUTI POVYShENIYa KAChESTVA LEChENIYa BOL'NYKh KhRONIChESKOY SERDEChNOY NEDOSTATOChNOST'Yu PRI KhRONIChESKOY BOLEZNI POChEK


Cite item

Full Text

Abstract

Epidemiology and prognostic significance of chronic kidney disease in chronic heart failure patients are discussed, methods of their treatment are summarized

About the authors

- -

References

  1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Co.. Cardiol. 1992; 20: 248 - 254
  2. Abraham W.T., Schrier R.W. Renal function in congestive heart failure. In: Greenberg A. (ed.) Primer on kidney diseases., 2nd ed. San-Diego: Academic Press; 1998: 183 - 187
  3. Hall W.D. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am. J. Med. Sci. 1999; 317: 176 - 182
  4. Matsusaka I., Hymes J., Ischikawa I. Angiotensin in progressive renal diseases: theory and practice. J. Am. Soc. Nephrol. 1996; 7: 2025 - 2043
  5. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol. Dial. Transplant. 1999; 14 (Suppl. 1): 42 - 44
  6. Matsushima H., Yoshida H., Machiguchi T. et al. Urinary albumin and TGF-β1 levels as renal damage indices in patients with congestive heart failure. Clin. Exp. Nephrol. 2002; 6: 21 - 29
  7. Yoshida H., Yashiro M., Liang P. et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int. 1998; 53: 880 - 891
  8. Goldfarb M., Abassi Z., Rosen S., Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int. 2001; 60: 607 - 613
  9. Knight E.L., Glynn R.J., McIntyre K.M. et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am. Heart J. 1999; 138 (5 Pt. 1): 849-855.
  10. Metra M., Nodari S., Parrinello G. et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur. J. Heart Fail. 2008; 10(2): 188-195
  11. Damman K., Navis G., Voors A.A. et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J. Card. Fail. 2007; 13(8): 599-608
  12. Hebert K., Dias A., Delgado M.C. et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur. J. Heart Fail. 2010 May 19. [Epub ahead of print]
  13. Butler J., Forman D.E., Abraham W.T. et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. 2004; 147(2): 331-338
  14. Cowie M.R., Komajda M., Murray-Thomas T. et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur. Heart J. 2006; 27(10): 1216-1222
  15. Damman K., van Veldhuisen D.J., Navis G. et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur. J. Heart Fail. 2008; 10(10): 997-1000
  16. Damman K., Van Veldhuisen D.J., Navis G. et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010; 96(16): 1297-1302
  17. Rosenstock J.L., Gilles E., Geller A.B. et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int. Urol. Nephrol. 2010 Jul 4. [Epub ahead of print]
  18. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 1999; 106 (5B): 13S - 24S
  19. Clive D.M., Stoff J.S. Renal syndromes, associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1984; 310: 563 - 572
  20. Perazella M.A., Eras J. Are selective COX-2 inhibitors nephrotoxic? Am. J. Kidney Dis. 2000; 129: 1423 - 1430
  21. Dzau V.J., Packer M., Lilly L.S. et al. Prostaglandins in severe congestive heart failure. Relation to activation of renin-angiotensin system and hyponatremia. N. Engl. J. Med. 1984; 310: 347 - 352
  22. Heerdink E.R., Leufkens H.G., Herings R.M. et al. NSAIDs associated with increased risk in elderly patients taking diuretics. Arch. Intern. Med. 1998; 158: 1108 - 1112
  23. Weinberg M.S., Quigg R.J., Salant D.J., Bernard D.B. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40: 216 - 218
  24. Ducloux D., Jamali M., Chalopin J.M. Chronic congestive heart failure associated with bilateral renal artery stenosis. Clin. Nephrol. 1997; 48: 54 - 55
  25. Gray B.H., Olin J.W., Childs M.B. et al. Clinical benefit of renal artery angioplasty with stenting for the control of the recurrent and refractory congestive heart failure. Vasc. Med. 2002; 7: 275 - 279
  26. de Silva R., Nikitin N.P., Bahndari S. et al. Atherosclerotic renovascular disease in chronic heart failure: should we intervene? Eur. Heart. J. 2005; 26: 1596 - 1609
  27. Svensson M., Gustafsson F., Galatius S. et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J. Card. Fail. 2004; 10(4): 297-303
  28. ОССН ВНОК. Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердечная недостаточность. 2005; 2(36): 2 - 21
  29. The ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 2005; 26(11): 1115-1140
  30. Auchus R.A. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr. Opin. Nephrol. Hypertens. 2003; 12: 153 - 158
  31. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709 - 717
  32. Rossi J., Bayram M., Udelson J.E. et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care. 2007; 9(2): 82-86
  33. Beukhof C.M., Hoorn E.J., Lindemans J., Zietse R. Novel risk factors for hospital-acquired hyponatraemia: a matched case-control study. Clin. Endocrinol. (Oxf.) 2007; 66(3): 367-372
  34. Bissram M., Scott F.D., Liu L., Rosner M.H. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern. Med. J. 2007; 37(3): 149-155
  35. Gill G., Huda B., Boyd A. et al. Characteristics and mortality of severe hyponatraemia - a hospital-based study Clin. Endocrinol. (Oxf). 2006; 65(2): 246-249
  36. Chow K.M., Szeto C.C., Wong T.Y. et al. Risk factors for thiazide-induced hyponatraemia. Q.J.M. 2003; 96(12): 911-917
  37. Hoorn E.J., Lindemans J., Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol. Dial. Transplant. 2006; 21(1): 70-76
  38. Szatalowitz V.L., Arnbold P.E., Chaimpovitz C. et al. Radio immunoassay of plasma arginine vasopressin in hyponatriemic patients with congestive heart failure. N. Engl. J. Med. 1981; 305: 263 - 266
  39. Kalra P.R., Anker S.D., Coats A.J.S. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovascular Res. 2001; 51: 495 - 509
  40. Carmichael M.C., Kumar R. Molecular biology of vasopressin receptors. Semin. Nephrol. 1994; 14: 341 - 348
  41. Nielsen S., Chou C.L., Marples D. et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl. Acad. Sci. USA 1995; 92: 1013 - 1017
  42. Nielsen S., Kwon T.-W., Monster B. et al. Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. 1999; 10: 647 - 663
  43. Kwon T.H., Hager H., Nejsum L.N. et al. Physiology and pathophysiology of renal aquaporins. Semin. Nephrol. 2001; 21: 231 - 238
  44. Martin P.Y. Recent advances in the understanding of water metabolism in heart failure (involvement of aquaporin). Kidney Blood Press. Res. 2000; 23:193 - 194
  45. Xu D., Yin X., Hui H., Deng Y., Ren H. Urinary excretion of aquaporin-2 water channel protein in chronic heart failure rats. Chin. Med. J. 2001;114: 899 - 901
  46. Wong N.L., Tsui J.K. Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Metabolism 2002; 51: 970 - 975
  47. Gros P., Palm C. The treatment of hyponatraemia using vasopressin antagonists. Exp. Physiol. 2000; 85S: 7S - 18S
  48. Schrier R.W., Gross P., Gheorghiade M. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006; 355(20): 2099-2112
  49. Gheorghiade M., Niazi I., Ouyang J. et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003; 107(21): 2690-2696
  50. Ghali J.K., Koren M.J., Taylor J.R. et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 2006; 91(6): 2145-2152
  51. Greenberg A. Diuretic complications. Am. J. Med. Sci. 2000; 319: 10 - 24
  52. Spieker L.E., Ruschitzka F.T., Luscher T.F., Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur. J. Heart Failure 2002; 4: 403 - 410
  53. Naafs M.A., van der Hoek C., van Duin S. et al. Decreased renal clearance of digoxin in chronic congestive heart failure. Eur. J. Clin. Pharmacol. 1985; 28: 249 - 252
  54. Ghali J.K., Wikstrand J., Van Veldhuisen D.J. et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J. Card. Fail. 2009; 15(4): 310-318
  55. Castagno D., Jhund P.S., McMurray J.J. et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur. J. Heart Fail. 2010; 12(6): 607-616
  56. Dupont A.G. Carvedilol and the kidney. Clin. Investig. 1992; 70 (Suppl 1): S127-S131
  57. Ito H. Nagatomo Y. Kohno T. et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circ. J. 2010; 74(8): 1578-1583
  58. Kittleson M., Hurwitz S., Shah M.R. et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J. Am. Coll. Cardiol. 2003; 41(11): 2029-2035
  59. Jackson B., Cubela R.B., Conway E.L., Johnston C.I. Lisinopril pharmacokinetics in chronic renal failure. Br. J. Clin. Pharmacol. 1988; 25(6): 719-724
  60. Johnson E.S., Weinstein J.R., Thorp M.L. et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol. Drug Saf. 2010; 19(3): 266-272
  61. Simpson K., Jarvis B. Lisinopril: a review of its use in congestive heart failure. Drugs. 2000; 59(5): 1149-1167
  62. Massie B.M., Armstrong P.W., Cleland J.G. et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161(2): 165-171
  63. Cinotti G.A., Zucchelli P.C.; Collaborative Study Group. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol. Dial. Transplant. 2001; 16(5): 961-966
  64. Шилов А.М., Мельник М.В., Осия А.А. Влияние ингибитора АПФ на реологию крови при артериальной гипертензии. Врач 2010; 6: 35-40
  65. Шишкин А.Н., Бирюкова Е.Н. Нефропротекция у больных сердечной недостаточностью. Вестник клинической медицины 2002; 1: 18-21
  66. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; 6: 39-46
  67. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7 - 15
  68. Ronco C., McCullough P.A., Anker S.D. et al.; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib. Nephrol. 2010; 165: 54-67

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies